Abbott Adds Epigenetics To Its Anticancer R&D Through EpiTherapeutics Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Abbott broadens its approach to new cancer therapies by linking up with the Danish company EpiTherapeutics on modifying epigenetic regulation.